Loading
Every dated change on the records linked to PD-L1-high gastric cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
CPS ≥5: OS 14.
Pembrolizumab alone was non-inferior to chemotherapy for overall survival in PD-L1-positive disease; pembrolizumab plus chemotherapy was not superior to chemotherapy; large benefit in the microsatellite-unstable subgroup.
Nivolumab improved overall survival over placebo in heavily pretreated advanced gastric cancer; approved in Japan in September 2017.
A milestone in how this cancer is treated.